A new experimental vaccine of messenger RNA (mRNA) could reduce by approximately 65% the possibility of cancer recurrence in cases of melanoma that have a significant risk of tumor reproduction, reported today the Cantonal Hospital of Geneva.
This medical center will participate in a phase 3 trial organized globally and that it will start in a few weeks and will last until the last quarter of the yeardeclared the head of its Oncology Department, Olivier Michielin.
Per capita income may influence skin cancer death rates
“Extremely impressive” conclusions
Michielin called the findings “extremely impressive” achieved in a recent international oncology meeting in relation to the fact that the mRNA vaccine that is being tested, in combination with taking a medication, allows a significant reduction in skin cancer recurrence.
These results imply a revolution in the field of cancer vaccinology since, he added, “they allow for the first time to target many specific mutations”the researcher told the newspaper Le Temps.
The oncologist also stressed that lthe low toxicity of this vaccine makes it a possibility for those patients who are not offered immunotherapy due to risk of transplant rejection.
2023-06-07 11:54:03
#investigate #RNA #vaccine #reduces #risk #skin #cancer #reproduction
